From discovery to the clinic — our roadmap for bringing RadioPDT to patients.
Multiple programs advancing through preclinical and clinical stages, with our lead candidate DPX-01 targeting recurrent glioblastoma.
Our pipeline spans multiple indications and platform extensions.
Lead program targeting recurrent glioblastoma multiforme. Currently advancing through preclinical studies with IND-enabling activities planned for 2027. First-in-human Phase I trials targeted for 2028.
Expanding the DPX-01 platform to treat bone metastases from solid tumors. Preclinical studies in osteolytic lesion models. Discovery phase initiated in 2026.
Next-generation formulation optimized for hypoxic tumor microenvironments. Prostate cancer represents a large addressable market with significant unmet need in castration-resistant disease.
Advanced nanoparticle formulation with selective drug release capabilities. Combines RadioPDT with targeted chemotherapy payload for enhanced anti-tumor effect in glioblastoma.
Combination of RadioPDT with immune checkpoint modulation. Leverages radiation-induced immunogenic cell death to prime anti-tumor immune response for durable cancer control.
Theranostic platform combining therapy with real-time imaging. Enables visualization of nanoparticle distribution and treatment response for personalized dosing.